arXiv:2606. 02228v1 Announce Type: cross Abstract: Predicting whether an individual with Alzheimer's disease will experience mild or severe disease progression is essential for personalized treatment.
By Clara Hoffmann, Nadja Klein
arXiv:2606. 15784v1 Announce Type: new Abstract: Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade.
By Nguyen Linh Dan Le
Alzheimer's disease (AD) progression is often described through the amyloid-tau-neurodegeneration, or AT(N), cascade. However, most longitudinal models represent this cascade either as a fixed sequence of biomarkers or as a black-box forecasting task.
arXiv:2606. 24604v1 Announce Type: new Abstract: Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is.
By Arya Hariharan, Shreyank N Gowda, Anala M R
Longitudinal modelling of Alzheimer's disease progression is clinically useful only if it can describe not just the most likely next diagnosis, but how a patient may evolve over time and how reliable that forecast is. Most deep learning approaches reduce this problem to single-step classification, treating cognitively normal, mild cognitive impairment, and dementia as flat categories while providing limited insight into how uncertainty accumulates across future visits.
arXiv:2606. 09671v1 Announce Type: cross Abstract: Alzheimer's disease (AD) progression is highly heterogeneous and is typically observed through sparse and irregular longitudinal data, posing challenges for prediction and personalised monitoring.
By Yinyu Huang, Yilin Zhang, Sofia Michopoulou, Christopher Kipps, Rahman Attar